Business Wire

JAMESTOWN

10.11.2020 10:02:17 CET | Business Wire | Press release

Share
Jamestown Expands European Business

Global real estate company Jamestown today announced the acquisition of three historic office buildings in the up-and-coming Mülheim area of Cologne – the city that is home to Jamestown’s European headquarters. The acquisition marks the firm’s first-ever acquisition in Germany, and its second in Europe in less than a year.

Formerly an industrial neighborhood, Mülheim has, over the past decade, become a thriving area of redevelopment that attracts companies seeking creative spaces. Constructed between 1890 and 1914, the buildings at Schanzenstrasse 22, 24, and 28 are home to a mix of multi-media and entertainment companies, including prominent television production company Brainpool TV. The 34,545-square meter buildings are an attractive blend of post-industrial architecture. Jamestown purchased the buildings with two institutional investors from a group of private investors.

“We have been investing in US real estate from Cologne for 37 years. Our first project in Germany is an important milestone for Jamestown. One of our core competencies at Jamestown is the revitalization of old industrial buildings and we see great potential for this in Europe as well, ” said Christoph Kahl, Chairman of Jamestown.

Jamestown has a long track record of revitalizing historic, industrial buildings into neighborhood destinations and office hubs specializing in technology and content creation. This development strategy has proven to be an economically, socially, and environmentally responsible alternative to new construction. Jamestown prides itself on preserving cities’ industrial pasts, while bringing new life into local communities. Its leadership team continues to see many opportunities to expand this adaptive reuse strategy across Europe, with its rich industrial heritage and strong urban cultures.

“We are excited to add Schanzenstrasse to our growing European footprint. Technology, media, and content firms are resilient, durable sectors that are thriving in the current market. Our focus is on mixed-use projects that create ecosystems where businesses can connect to one another and the consumer. Mülheim, and our other neighbors, are part of that ecosystem,” said Michael Phillips, President of Jamestown.

Jamestown worked with DLA Piper and the seller with McDermott, Will & Emery for legal counsel. The seller was represented by Tresono Family Office. The property will be managed by Apleona Real Estate GmbH.

Since it was established in 1983, Jamestown has been a recognizable name in Germany for operating real estate funds and as a leading landlord and property manager of mixed-use projects in the U.S. that offer commercial office, residential, and retail spaces.

Jamestown made its first European acquisition in December 2019, when it bought the historic Groot Handelsgebouw in Rotterdam, the Netherlands. The company’s roughly $12 billion / EUR 10 billion portfolio includes some of the most iconic buildings and landmarks in the U.S. including One Times Square in New York, Ghirardelli Square in San Francisco, and Ponce City Market in Atlanta.

###

About Jamestown
Jamestown was established in 1983 as an investment and management company focused on income-producing real estate in the United States. Since then, Jamestown has grown its portfolio of assets in key markets throughout the U.S. and expanded its investment footprint to South America and Europe. Jamestown's capabilities include acquisitions, capital markets, property management, asset management, retail leasing, design, sustainability, and risk management. Jamestown has headquarters in Cologne, Germany and Atlanta, Georgia and offices in Amsterdam, New York, Boston, San Francisco, Los Angeles, and Bogota, Colombia. For more information, visit www.jamestownlp.com .

Photos:
https://jamestown.canto.com/b/G7E1O

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye